Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 15;6(6):177-83.
doi: 10.4251/wjgo.v6.i6.177.

Current status of pharmacological treatment of colorectal cancer

Reyhan Akhtar  1 , Shammy Chandel  1 , Pooja Sarotra  1 , Bikash Medhi  1
Affiliations

Current status of pharmacological treatment of colorectal cancer

Reyhan Akhtar et al. World J Gastrointest Oncol. .

Abstract

Aim: To review the clinical trials for the development in drugs for chemotherapeutic treatment of colorectal cancer (CRC).

Methods: A systematic review identified randomized controlled trials (RCTs) assessing drugs for the treatment of CRC or adenomatous polyps from www.clinicaltrials.gov. Various online medical databases were searched for relevant publications.

Results: Combination treatment regimens of standard drugs with newer agents have been shown to improve overall survival, disease-free survival, time to progression and quality of life compared to that with standard drugs alone in patients with advanced colorectal cancer. The FOLFOXIRI regimen has been associated with a significantly higher response rate, progression-free survival and overall survival compared to the FOLFIRI regimen.

Conclusion: Oxaliplatin plus intravenous bolus fluorouracil and leucovorin has been shown to be superior for disease-free survival when compared to intravenous bolus fluorouracil and leucovorin. In addition, oxaliplatin regimens were more likely to result in successful surgical resections. First line treatment with cetuximab plus fluorouracil, leucovorin and irinotecan has been found to reduce the risk of metastatic progression in patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases. The addition of bevacizumab has been shown to significantly increase overall and progression-free survival when given in combination with standard therapy.

Keywords: 5-fluorouracil; Chemotherapy; Colorectal cancer; Epidermal growth factor receptor inhibitor; Leucovorin; Metastasis.

PubMed Disclaimer

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. International Agency for Research on Cancer. World Cancer Report 2008. Boyle P, LevinI B, editor. Available from: http: //www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php.
    1. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119:2657–2664. - PubMed
    1. Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2007;120:664–671. - PubMed
    1. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–2547. - PubMed